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Abstract W-Conotoxin GIIIA, a peptide toxin isolated from the
marine snail Conus geographus, preferentially blocks skeletal
muscle sodium channels in vertebrates. In this study, analogs of
W-conotoxin GIIIA in which essential Arg-13 was replaced with
arginine analogs consisting of a piperidyl framework to regulate
length and direction of the side chain were synthesized.
Synthesized analogs exhibited similar CD and NMR spectra to
that of GIIIA, suggesting a three-dimensional structure identical
to that of the native toxin. The biological activities of piperidyl
analogs were decreased or lost despite the small change in the
side chain of Arg-13. The investigated structure^activity
relationships in inhibiting electrically stimulated muscle contrac-
tion suggest that the guanidinium group at amino acid position 13
interacts best when spaced with three to four carbons and placed
in a vertical direction from the peptide loop. Thus, the position of
the guanidinium group at Arg-13 of GIIIA must be located in a
certain range for its strong interaction with the channel
protein. ß 2001 Published by Elsevier Science B.V. on behalf
of the Federation of European Biochemical Societies.
Key words: W-Conotoxin GIIIA; Sodium channel; Twitch
contraction
1. Introduction
It is well known that some cone snails produce highly
strong venom to hunt [1]. W-Conotoxin GIIIA (GIIIA) is
one of the toxins isolated from Conus geographus [2]. Toxicity
was caused by the preferential block of the skeletal muscle
type sodium channels, binding to the site which overlaps the
tetrodotoxin and saxitoxin binding sites [3]. GIIIA is consti-
tuted of 22 amino acid residues, compactly packed with three
disul¢de bridges and three hydroxyproline residues. These di-
sul¢de bridges are indispensable to inhibit sodium channels.
Point mutational studies for GIIIA suggested that Arg-13 of
GIIIA may be responsible for the strong binding activity [4,5].
Further, Chang et al. [6] suggested that Arg-13 interacts with
Glu-758 in domain II of the rat skeletal muscle sodium chan-
nel with approx. 3 kcal/mol, and that about half was electro-
static and half non-electrostatic interaction. More or less in
the potency of biological activity, other responsible residues of
GIIIA have been studied on rat skeletal muscle sodium chan-
nels [7^10]. These previous analyses on the interaction of
GIIIA with sodium channels have been achieved mainly by
the replacement of standard amino acids with other amino
acids. Accordingly, we focused here on the role of Arg-13 in
the interaction with sodium channels by synthesizing analogs
of GIIIA in which Arg-13 was replaced with the Arg analogs
containing a piperidyl framework to regulate the direction and
length of the side chain (Fig. 1). The resulting structure^ac-
tivity relationship provides some precise information on the
spatial placement of the Arg guanidinium group. The novel
strategy, modi¢cation of the side chain of a single responsible
amino acid in the peptide or protein, may be useful to de¢ne
the molecular interaction between peptide ligands and its ef-
fectors.
2. Materials and methods
2.1. Materials
9-Fluorenylmethoxycarbonyl (Fmoc)-amino-(1-carbamimidoylpi-
peridin-4-yl)acetic acid (R1) [2,2,5,7,8-pentamethylchroman-6-sulfonyl
(Pmc)]-OH, Fmoc-2-amino-3-(1-carbamimidoylpiperidin-4-yl)pro-
pionic acid (R2) (Pmc)-OH and Fmoc-2-amino-4-(1-carbamimidoylpi-
peridin-4-yl)butyric acid (R3) (Pmc)-OH were purchased from RSP
Amino Acid Analogues, Inc. (MA, USA). Other Fmoc-amino acid
was purchased from Watanabe Chemical Industries (Hiroshima, Ja-
pan). Fmoc-NH-resin and other reagents used on a synthesizer were
obtained from Perkin Elmer-Applied Biosystems (Tokyo, Japan).
2.2. Synthesis and puri¢cation of peptide
Solid phase peptide synthesis was performed on a 433A peptide
synthesizer (Perkin Elmer-Applied Biosystems). Matrix-assisted laser
desorption/ionization time-of-£ight mass spectrometry (MALDI-
TOF-MS) was carried out with a Voyager DE Pro mass spectrometer
(PerSeptive Biosystems, Tokyo, Japan) using K-cyano-4-hydroxycin-
namic acid as a matrix. Analytical reverse phase (RP)-high perform-
ance liquid chromatography (HPLC) was conducted on a Jasco 1500
system (Jasco, Tokyo, Japan) with an ODS column Develosil ODS-
MG-5 (3.0U150 mm, Nomura Chemicals, Aichi, Japan). Preparative
RP-HPLC was performed on a Jasco 1500 system with an ODS col-
umn Develosil ODS-5 (20U250 mm, Nomura Chemicals). GIIIA ana-
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logs were synthesized by a procedure similar to that described previ-
ously [4,11]. Brie£y, linear precursors of GIIIA analogs were synthe-
sized by solid phase methodology of Fmoc chemistry. Arg-13 residue
was incorporated using Fmoc-R1(Pmc)-OH, Fmoc-R2(Pmc)-OH and
Fmoc-R3(Pmc)-OH. After tri£uoroacetic acid cleavage, crude linear
peptide was diluted to the ¢nal peptide concentration of 0.05 mM and
subjected to oxidative disul¢de bond formation in 0.2 M ammonium
acetate bu¡er (pH 7.8) for 1 day. The crude cyclic products were
puri¢ed by successive chromatography on Sephadex G-50F, CM-cel-
lulose CM-52 and preparative HPLC with an ODS column. The pu-
rity and structure of synthetic peptides were con¢rmed by analytical
HPLC and MALDI-TOF-MS measurements, respectively.
2.3. CD and NMR measurements
All the CD spectra were measured on a JASCO J-720 spectropo-
larimeter (Jasco) in H2O solution (0.01 M sodium phosphate, pH 7.0)
at 20‡C at peptide concentrations of 0.05 mM for 190^250 nm and
1 mM for 240^360 nm using a quartz cell of 1 mm path length. The
spectra are expressed as molecular ellipticity [a] in degree cm2 dmol31.
NMR spectra were recorded on a Bruker AM-400 spectrometer
(Bruker, Ibaragi, Japan) operating at 400 MHz for proton frequency.
Peptides were dissolved in 90% H2O/10% 2H2O to approx. 2 mM.
2.4. Bioassay
Inhibitory e¡ects of synthesized analogs on the twitch contraction
of skeletal muscle to direct electrical stimuli were assayed, as reported
previously [4,11,12]. Male Wistar rats (body weight 200^300 g) were
stunned and bled. Diaphragm muscle was excised and cut into four
strips, which were electrically stimulated with 5 ms pulses at 0.1 Hz
(supramaximal voltage). Twitch-tension responses were recorded iso-
metrically. The activity of the peptides was expressed as percent inhi-
bition of twitch response.
3. Results and discussion
The linear precursor peptides for R13R1-GIIIA, R13R2-
GIIIA and R13R3-GIIIA were synthesized using conventional
Fmoc chemistry, and cleaved from resin. Disul¢de bonds were
formed by air oxidation, giving crude products of GIIIA ana-
logs with 1% overall isolation yield. The products were puri-
¢ed by HPLC. Analytical HPLC exhibited a single peak for
each product (data not shown), suggesting high purity. The
products were analyzed using MALDI-TOF-MS (R13R1-
GIIIA: m/z 2634.0 (calcd = 2634.1), R13R2-GIIIA: m/z
2648.1 (calcd = 2648.2), R13R3-GIIIA: m/z 2662.2 (calcd =
2662.2)).
The three-dimensional structure of GIIIA analogs was con-
¢rmed by CD and 1H NMR spectra. The CD spectra showed
that all tested GIIIA analogs had a secondary structure sim-
ilar to that of GIIIA (Fig. 2, left panel). The 1H NMR spectra
of these GIIIA analogs were compared to estimate the chem-
ical shift values between the K-proton of each amino acid and
the value of the random coil [13]. Each K-proton of the amino
acids of the GIIIA analogs had chemical shifts similar to
those of GIIIA, except for the substituted residue at position
13 (Fig. 2, right panel), supporting their structural similarity.
Taken together, the data indicate that synthesized R13R1-
GIIIA, R13R2-GIIIA and R13R3-GIIIA have a three-dimen-
sional structure similar to that of native GIIIA.
The biological activities of GIIIA analogs were measured
by analyzing their e¡ects on the contractile response of the
isolated rat diaphragm to direct electrical stimulation as pre-
viously described [4,11,12] (Fig. 3). The derivative of R13R1-
GIIIA elicited a dose-dependent inhibition of the contractile
response. R13R1-GIIIA was approx. 20 times less potent than
GIIIA. The other derivatives tested, R13R2- and R13R3-
GIIIA, only elicited a small contractile inhibition of less
than 10% at the relatively high concentration of 3 WM, indi-
cating a marked loss in activity (Table 1). These results sug-
gest that R1, but not R2 and R3, is e¡ectively substituted with
Arg-13 for exerting biological action, though a little less po-
tent than native GIIIA.
Our previous results concerning the e¡ects of modi¢cation
at Arg-13 of GIIIA on biological activity [5] are also summa-
rized in Table 1 and Fig. 3. The replacement of Arg-13 with
Fig. 1. The structure of W-conotoxin GIIIA (upper) and amino acids introduced to the Arg-13 position (bottom). Dotted lines are disul¢de
bonds. The numbers indicate the amino acid order from the N-terminal region.
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Ala (R13A-GIIIA) markedly reduced the potency of action to
less than 1/300 compared with that of native GIIIA. When
amino acids at positions 12^13 or 13^14 were shu¥ed (D12R-
R13D-GIIIA or R13Q-Q14R-GIIIA), the potency of action
was markedly attenuated. On the other hand, the replacement
of Arg-13 with another basic amino acid of Lys (R13K-
GIIIA) elicited a moderate reduction of approximately one
tenth in the activity. Further, the replacement with homoArg
(R13homoArg-GIIIA), having the aliphatic side chain of Arg
elongated by one carbon from the peptide loop, did not sig-
ni¢cantly alter the potency of action. Consequently, the exact
placement of a basic amino acid, preferentially Arg, at posi-
tion 13 in GIIIA will be pivotal for the biological action. In
addition, the number of carbon atoms in the aliphatic side
chain protruding from the peptide loop may be variable at
least in the range of 3^4 (three for Arg and four for Lys and
homoArg) for exerting activity.
In the present experiments, a modi¢cation of Arg-13 with
charged groups of R2 and R3 reduced the activity less than
the replacement with Ala (a non-charged residue). Presum-
ably, modi¢cation with a piperidine structure causes steric
interference with the binding to sodium channels. Thus, the
marked loss of activity in R13R2- and R13R3-GIIIA analogs
may be attributed to not only loss of interaction but also
addition of a steric repulsive force.
Incorporation of piperidine into the side chain at position
13 of GIIIA, in the present experiments, can provide more
information on the chemical structure around Arg-13 for bio-
logical activity. For the R1 molecule, which has three carbon
atoms between the peptide loop and nitrogen, the rotation of
the C^C or C^N bond does not change the spatial position of
the guanidinium group that is located nearly in a vertical
direction from the peptide loop, while R2 has four carbon
atoms in which three carbons are in piperidine, and the gua-
nidinium group probably inclines by 60^70‡ from the vertical
line with the peptide loop. In molecules of Arg, homoArg and
Lys that possess three to four carbon atoms in the side chain
to nitrogen, the guanidinium group or amino group can be
placed in a nearly vertical direction from the peptide loop due
to the rotation of the responsible C^C bond. When comparing
the biological activity among the tested compounds having
three to four carbon atoms in the side chain, only the sub-
stitute for R2 lost its activity, while the others retained it. The
loss of activity of R13R2-GIIIA may be due to the fact that
the inclination of the guanidinium group from the vertical axis
in R2 interferes with the access of the guanidinium group to
the receptive site of the channel protein, or brings about the
neutralization of the basic charge of the guanidinium group
due to interaction with the neighboring Asp-12. Although the
replacement with R3 elicited a loss in activity, the substituent
R3 has ¢ve carbon atoms (three in piperidine) from the pep-
tide loop and the guanidinium group can be placed in a nearly
vertical direction from the peptide loop. The length of the side
chain from the peptide loop, and the guanidinium group in
R3 may be too far to exert biological action. Rather, the
guanidinium group may be better located in a vertical position
and be separated by three to four aliphatic carbon atoms from
Fig. 2. CD spectra of GIIIA and its analogs (left) and NMR chemical shift di¡erence between the K-protons of GIIIA analog residues and the
random coil value (right). A: GIIIA; B: R13R1-GIIIA; C: R13R2-GIIIA; D: R13R3-GIIIA.
Fig. 3. Dose^inhibition curves for GIIIA and its analogs in twitch
responses of isolated rat diaphragm to electrical stimuli. Ordinate
represents the percent value of inhibition of contractile response.
The data with asterisks are from [5].
Table 1
Inhibitory activity of GIIIA and its analogs on skeletal muscle con-
traction to electric stimulation
Compound Inhibitory
activity IC50 (WM)
IC50/IC50
(native GIIIA)
GIIIA 0.10 1.0
R13A-GIIIAa 42 420
R13K-GIIIAa 1.12 11.2
R13homoArg-GIIIAa 0.2 2
D12R-R13D-GIIIAa s 30 s 300
R13Q-Q14R-GIIIAa s 30 s 300
R13R1-GIIIA 1.64 16.4
R13R2-GIIIA s 3.00 s 30
R13R3-GIIIA s 3.00 s 30
aFrom [5].
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the peptide loop of GIIIA for proper interaction with sodium
channels.
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